A causal role for TRESK loss of function in migraine mechanisms
Pettingill P., Weir GA., Wei T., Wu Y., Flower G., Lalic T., Handel A., Duggal G., Chintawar S., Cheung J., Arunasalam K., Couper E., Haupt LM., Griffiths LR., Bassett A., Cowley SA., Cader MZ.
The two-pore potassium channel TRESK is a potential drug target in pain and migraine. Pettingill et al. show that the F139WfsX2 mutation causes TRESK loss of function and hyperexcitability in nociceptors derived from iPSCs of patients with migraine. Cloxyquin, a TRESK activator, reverses migraine-relevant phenotypes in vitro and in vivo.